COMPANY

Merida Biosciences

HQ: Cambridge, MA source · meridabio.com ↗

Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies in immune-mediated conditions. From company website Source · Oct 12, 2026

Keywords: antibodies Graves Disease

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Dec 19, 2025 Trial start Phase 1: NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease source ↗

Upcoming milestones

Jul 24, 2028 (ESTIMATED) · Phase 1 · NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease · NCT07305818

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07305818	NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease	Phase 1	Recruiting	Dec 19, 2025	Jul 24, 2028 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗